A phase I/II study of rapamycin (sirolimus) in combination with methotrexate (MTX) and cyclosporine [ciclosporin] (CPS) in patients undergoing marrow transplantation from related donors mismatched for one HLA [human leukocyte antigen] antigen in the direction of graft-versus-host disease (GVHD).

Trial Profile

A phase I/II study of rapamycin (sirolimus) in combination with methotrexate (MTX) and cyclosporine [ciclosporin] (CPS) in patients undergoing marrow transplantation from related donors mismatched for one HLA [human leukocyte antigen] antigen in the direction of graft-versus-host disease (GVHD).

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 21 Jun 2010

At a glance

  • Drugs Sirolimus (Primary) ; Ciclosporin; Methotrexate
  • Indications Graft-versus-host disease
  • Focus Adverse reactions
  • Most Recent Events

    • 21 Jun 2010 Status changed from active, no longer recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 19 Dec 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top